The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Assam is home to more than 1,700 species of medicinal plants
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Subscribe To Our Newsletter & Stay Updated
